Table 2.
Decline in FVC% in placebo group over 12 months
| N | Decline in FVC% predicted, Mean (SD) | P value | |
|---|---|---|---|
| Disease duration, years | |||
| 0–2 | 17 | 4.4 (18.8) | 0.85 |
| 2–4 | 29 | 4.4 (10.1) | |
| >4 | 18 | 3.5 (10.1) | |
|
| |||
| HRCT Fibrosis score | |||
| 0–2 | 40 | 2.7 (12.8) | 0.008 |
| 3–4 | 25 | 7.2 (11.8) | |
|
| |||
| HRCT Ground Glass Opacity score | |||
| 0–1 | 55 | 4.9(13.0) | 0.61 |
| 2–3 | 10 | 1.8 (9.8) | |
|
| |||
| HRCT Honeycombing | |||
| 0 | 38 | 3.8 (14.5) | 0.96 |
| ≥1 | 27 | 5.3 (9.2) | |
|
| |||
| Autoantibodies | |||
| SCL-70 | 17 | 5.2 (9.1) | 0.88 |
| Anti-Polymerase-III/anti-centromere | 5 | 6.9 (11.5) | |
| Others | 26 | 4.4 (11.8) | |
|
| |||
| Overall | 66 | 4.2(12.8) | |